Skip to content

Observational Cohort Study of Advanced Non-small Cell Lung Cancer (CAPTRA-LUNG)

Observational Cohort Study of Advanced Non-small Cell Lung Cancer (CAPTRA-LUNG)

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03334864
Enrollment
5000
Registered
2017-11-07
Start date
2022-11-03
Completion date
2025-12-31
Last updated
2023-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Non-small Cell Lung Cancer

Keywords

Advanced non-small cell lung cancer

Brief summary

Investigators propose to establish and maintain a cohort of patients with advanced non-small cell lung cancer, and to assess the treatment pattern, host genetic, and clinical factors which influence the prognosis and survival, as well as the interaction among these factors on disease diagnosis and treatment, short and long-term outcomes. Study type: Observational (Patient Registry) Study design: Observational Model: Cohort Time Perspective: Prospective and retrospective

Interventions

None listed

Sponsors

Peking Union Medical College Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Cohort I: diagnosis of advanced non-small cell lung cancer from 2012-2016; * Cohort II: documented positive driver gene mutations; and diagnosis of advanced non-small cell lung cancer; * Cohort III: diagnosis of advanced non-small cell lung cancer and in immune-therapy; * Cohort IV: diagnosis of advanced non-small cell lung cancer, and with wild-type driver gene or unknown driver gene status; * Cohort V: treated with anti-VEGF drug in first line, diagnosis of advanced non-squamous and non-small cell lung cancer in 6 months before recruit; * Age\>18 years; * Provision of written informed consent.

Exclusion criteria

* not applicable

Design outcomes

Primary

MeasureTime frameDescription
Overall Survival (OS)3 yearsOS was calculated from the diagnosis of advanced non-small cell lung cancer to death from any reasons

Countries

China

Contacts

Primary ContactYan Xu, M.D.
maraxu@163.com861069155039

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 23, 2026